39th Annual Congress of the European Association of Nuclear Medicine (EANM)

October 19, 2026 • 4:45pm - 6:15pm CEST

Vienna, Austria

ATNM-400 EANM 2026 Presentation Details

Abstract Title: First-In-Human Phase 1 Study of ATNM-400, Actinium-225 Antibody Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Abstract Number: OP-525
Presentation Type: Oral presentation
Session: 1111 — Theranostics Track: Prostate Cancer Therapy II
Session Date & Time: Monday, October 19, 2026, 4:45–6:15 p.m. CEST | Vienna, Austria
Location: Hall G1

2026 Annual Meeting of Stockholders

November 25, 2026 • 9:30am EDT

Garden City, NY

H.C. Wainwright 28th Annual Global Investment Conference

September 14, 2026 • 3:00pm - 3:30pm EDT

New York, NY

Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting

May 31–June 2, 2026

Los Angeles, California

AACR Annual Meeting

April 17–April 22, 2026

San Diego, CA